Earnings: Tough Times Ahead

Published on: 

Pharmaceutical Executive

Pharmaceutical Executive, Pharmaceutical Executive-03-01-2001, Volume 0, Issue 0

Sodertalje, Sweden-After two consecutive years of robust postmerger growth, AstraZeneca is facing a tough 2001. The company recorded a 16 percent increase in pretax profits for 2000, but CEO Tom McKillop advises that this year}s growth will be in the 5}6 percent range when Losec/Prilosec (omeprazole)-the world}s best-selling medicine-goes off patent and the US launch of its successor Nexium (esomeprazole) is delayed.